First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer

Sponsor
Vejle Hospital
Study ID
NCT01038037
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Carboplatin — DRUG
    i.v. day 1: AUC 5 x (GFR + 25) mg q3w
  • Vinorelbine — DRUG
    i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
  • panitumumab — DRUG
    i.v. day 1: 9 mg/kg q3w

Study Details

The purpose of this study is to determine whether the addition of panitumumab to standard chemotherapy in first-line treatment of advanced Non Small Cell Lung Cancer improves the treatment outcome. Patients are selected based on triple mutational status.

Key Dates

Start date
Jan 31, 2010
Status verified
Dec 2014
Primary completion
Jun 30, 2013
Completion
Dec 31, 2013

Study Design

Enrollment
23 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
FACTORIAL
Primary purpose
TREATMENT

Primary Outcome Measure

Response rate [ Time Frame: Up to 3 years ]

Related Studies